Heinz-Josef Lenz, MD - USC Norris ...

Dr. Heinz-Josef Lenz

Claim this profile

USC / Norris Comprehensive Cancer Center

Expert in Colorectal Cancer
Studies Colon Cancer
33 reported clinical trials
61 drugs studied

Area of expertise

1Colorectal Cancer
Global Leader
Heinz-Josef Lenz has run 19 trials for Colorectal Cancer. Some of their research focus areas include:
Stage IV
Stage III
dMMR positive
2Colon Cancer
Heinz-Josef Lenz has run 10 trials for Colon Cancer. Some of their research focus areas include:
Stage IV
Stage III
BRAF negative

Affiliated Hospitals

Image of trial facility.
USC / Norris Comprehensive Cancer Center
Image of trial facility.
Los Angeles County-USC Medical Center

Clinical Trials Heinz-Josef Lenz is currently running

Image of trial facility.

Genetic Testing

for Colorectal Cancer

This study aims to better understand the cause of colorectal cancer and how to find the best treatment for Hispanic patients with colorectal cancer. The genetic information in the blood and tissues may explain why patients who have the same type of cancer and receive the same treatment do not always have the same results. By combining genetic (certain qualities or traits passed from parents to offspring) information with clinical data, such as the responses of different kinds of cancers to different treatments, this study could lead to more knowledge about why certain cancers occur and why they respond differently to treatments. Information gathered from this study may help researchers match treatments to the genetics of each patient and the genetic changes in their tumor. This approach is known as personalized medicine.
Recruiting1 award N/A4 criteria
Image of trial facility.

Tucatinib + Trastuzumab + Chemotherapy

for Colorectal Cancer

This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable). Participants will be assigned randomly to the tucatinib group or standard of care group. The tucatinib group will get tucatinib, trastuzumab, and mFOLFOX6. The standard of care group will get either: * mFOLFOX6 alone, * mFOLFOX6 with bevacizumab, or * mFOLFOX6 with cetuximab mFOLFOX6 is a combination of multiple drugs. All of the drugs given in this study are used to treat this type of cancer.
Recruiting2 awards Phase 3

More about Heinz-Josef Lenz

Clinical Trial Related7 years of experience running clinical trials · Led 33 trials as a Principal Investigator · 7 Active Clinical Trials
Treatments Heinz-Josef Lenz has experience with
  • Ipilimumab
  • Cetuximab
  • Regorafenib
  • Nivolumab
  • Bevacizumab
  • Atezolizumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Heinz-Josef Lenz specialize in?
Is Heinz-Josef Lenz currently recruiting for clinical trials?
Are there any treatments that Heinz-Josef Lenz has studied deeply?
What is the best way to schedule an appointment with Heinz-Josef Lenz?
What is the office address of Heinz-Josef Lenz?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security